First Quadrant’s Castle Biosciences CSTL Stock Holding History

First Quadrant’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,501	Closed	-$166K	–	514
2021 Q3	$166K	Hold	2,501	–	–	0.02%	352
2021 Q2	$183K	Hold	2,501	–	–	0.02%	344
2021 Q1	$171K	Hold	2,501	–	–	0.02%	372
2020 Q4	$168K	Buy	+2,501	New	+$136K	0.02%	374
2020 Q3	–	Sell	-1,859	Closed	-$70K	–	637
2020 Q2	$70K	Buy	+1,859	New	+$63.5K	0.01%	614

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

First Quadrant's CSTL Position: Q4 2021 in Review

First Quadrant sold out of Castle Biosciences (CSTL) in Q4 2021, closing a stake of 2,501 shares — an estimated $166K sold.

First Quadrant first reported a position in CSTL in Q2 2020 and held it in 5 quarters. The position peaked at $183K in Q2 2021. 159 funds tracked by Wall St. Rank hold CSTL as of Q4 2021.

First Quadrant reported no remaining Castle Biosciences position as of Q4 2021 after selling out during the quarter.
First Quadrant sold 2,501 Castle Biosciences shares in Q4 2021, an estimated $166K.
First Quadrant first reported a position in Castle Biosciences in Q2 2020 and held it in 5 quarters.
First Quadrant's Castle Biosciences position peaked at $183K in Q2 2021.
159 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2021.

Based on First Quadrant's 13F filing for Q4 2021, filed 27 Jan 2022.